PortfoliosLab logoPortfoliosLab logo
XPEL vs. AMPH
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

XPEL vs. AMPH - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in XPEL, Inc. (XPEL) and Amphastar Pharmaceuticals, Inc. (AMPH). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, XPEL achieves a -9.58% return, which is significantly higher than AMPH's -24.98% return. Over the past 10 years, XPEL has outperformed AMPH with an annualized return of 47.20%, while AMPH has yielded a comparatively lower 2.48% annualized return.


XPEL

1D
-1.85%
1M
6.19%
YTD
-9.58%
6M
-10.65%
1Y
24.60%
3Y*
-16.42%
5Y*
-12.94%
10Y*
47.20%

AMPH

1D
-2.14%
1M
16.13%
YTD
-24.98%
6M
-20.50%
1Y
-22.19%
3Y*
-24.72%
5Y*
0.17%
10Y*
2.48%
*Multi-year figures are annualized to reflect compound growth (CAGR)

XPEL vs. AMPH - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
XPEL
XPEL, Inc.
-9.58%24.96%-25.83%-10.34%-12.04%32.43%251.95%140.10%335.82%0.00%
AMPH
Amphastar Pharmaceuticals, Inc.
-24.98%-27.88%-39.97%120.74%20.31%15.81%4.25%-3.07%3.43%4.45%

Correlation

The correlation between XPEL and AMPH is 0.29, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.29

Correlation (3Y)
Calculated over the trailing 3-year period

0.28

Correlation (5Y)
Calculated over the trailing 5-year period

0.23

Correlation (10Y)
Calculated over the trailing 10-year period

0.15

Correlation (All Time)
Calculated using the full available price history since Jun 25, 2014

0.13

The correlation between XPEL and AMPH shifts across timeframes, from 0.13 (all time) to 0.29 (1 year), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

XPEL:

$1.25B

AMPH:

$933.34M

EPS

XPEL:

$1.91

AMPH:

$1.67

PE Ratio

XPEL:

23.57

AMPH:

12.01

PEG Ratio

XPEL:

1.64

AMPH:

0.64

PS Ratio

XPEL:

2.55

AMPH:

1.32

PB Ratio

XPEL:

4.27

AMPH:

1.21

Total Revenue (TTM)

XPEL:

$489.75M

AMPH:

$720.53M

Gross Profit (TTM)

XPEL:

$208.35M

AMPH:

$341.13M

EBITDA (TTM)

XPEL:

$78.35M

AMPH:

$155.96M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

XPEL vs. AMPH — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

XPEL
XPEL Risk / Return Rank: 5858
Overall Rank
XPEL Sharpe Ratio Rank: 6262
Sharpe Ratio Rank
XPEL Sortino Ratio Rank: 5757
Sortino Ratio Rank
XPEL Omega Ratio Rank: 5656
Omega Ratio Rank
XPEL Calmar Ratio Rank: 5858
Calmar Ratio Rank
XPEL Martin Ratio Rank: 5959
Martin Ratio Rank

AMPH
AMPH Risk / Return Rank: 2323
Overall Rank
AMPH Sharpe Ratio Rank: 2323
Sharpe Ratio Rank
AMPH Sortino Ratio Rank: 2525
Sortino Ratio Rank
AMPH Omega Ratio Rank: 2424
Omega Ratio Rank
AMPH Calmar Ratio Rank: 2424
Calmar Ratio Rank
AMPH Martin Ratio Rank: 2020
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

XPEL vs. AMPH - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for XPEL, Inc. (XPEL) and Amphastar Pharmaceuticals, Inc. (AMPH). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


XPELAMPHDifference
Sharpe ratioReturn per unit of total volatility

+0.99

Sortino ratioReturn per unit of downside risk

+1.33

Omega ratioGain probability vs. loss probability

1.13

0.95

+0.17

Calmar ratioReturn relative to maximum drawdown

0.69

-0.53

+1.22

Martin ratioReturn relative to average drawdown

1.62

-1.07

+2.69

XPEL vs. AMPH - Sharpe Ratio Comparison

The current XPEL Sharpe Ratio is 0.54, which is higher than the AMPH Sharpe Ratio of -0.45. The chart below compares the historical Sharpe Ratios of XPEL and AMPH, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

XPEL vs. AMPH - Drawdown Comparison

The maximum XPEL drawdown since its inception was -99.44%, which is greater than AMPH's maximum drawdown of -74.05%. Use the drawdown chart below to compare losses from any high point for XPEL and AMPH.


Loading charts...

Drawdown Indicators


XPELAMPHDifference

Max Drawdown

Largest peak-to-trough decline

-99.44%

-74.05%

-25.39%

Max Drawdown (1Y)

Largest decline over 1 year

-31.79%

-45.25%

+13.46%

Max Drawdown (3Y)

Largest decline over 3 years

-71.47%

-74.05%

+2.58%

Max Drawdown (5Y)

Largest decline over 5 years

-75.62%

-74.05%

-1.57%

Max Drawdown (10Y)

Largest decline over 10 years

-75.62%

-74.05%

-1.57%

Current Drawdown

Current decline from peak

-55.49%

-69.09%

+13.60%

Average Drawdown

Average peak-to-trough decline

-52.41%

-24.08%

-28.33%

Ulcer Index

Depth and duration of drawdowns from previous peaks

13.55%

22.54%

-8.99%

Volatility

XPEL vs. AMPH - Volatility Comparison

The current volatility for XPEL, Inc. (XPEL) is 11.25%, while Amphastar Pharmaceuticals, Inc. (AMPH) has a volatility of 12.20%. This indicates that XPEL experiences smaller price fluctuations and is considered to be less risky than AMPH based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


XPELAMPHDifference

Volatility (1M)

Calculated over the trailing 1-month period

11.25%

12.20%

-0.95%

Volatility (6M)

Calculated over the trailing 6-month period

29.52%

46.17%

-16.65%

Volatility (1Y)

Calculated over the trailing 1-year period

40.53%

53.78%

-13.25%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

54.79%

45.07%

+9.72%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

63.67%

42.71%

+20.96%

Dividends

XPEL vs. AMPH - Dividend Comparison

Neither XPEL nor AMPH has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

XPEL vs. AMPH - Financials Comparison

This section allows you to compare key financial metrics between XPEL, Inc. and Amphastar Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


50.00M100.00M150.00M200.00M20222023202420252026
117.35M
171.17M
(XPEL) Total Revenue
(AMPH) Total Revenue
Values in USD except per share items

XPEL vs. AMPH - Profitability Comparison

The chart below illustrates the profitability comparison between XPEL, Inc. and Amphastar Pharmaceuticals, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

35.0%40.0%45.0%50.0%55.0%60.0%20222023202420252026
43.7%
41.1%
Portfolio components
XPEL - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, XPEL, Inc. reported a gross profit of 51.23M and revenue of 117.35M. Therefore, the gross margin over that period was 43.7%.

AMPH - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Amphastar Pharmaceuticals, Inc. reported a gross profit of 70.32M and revenue of 171.17M. Therefore, the gross margin over that period was 41.1%.

XPEL - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, XPEL, Inc. reported an operating income of 13.01M and revenue of 117.35M, resulting in an operating margin of 11.1%.

AMPH - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Amphastar Pharmaceuticals, Inc. reported an operating income of 13.63M and revenue of 171.17M, resulting in an operating margin of 8.0%.

XPEL - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, XPEL, Inc. reported a net income of 10.35M and revenue of 117.35M, resulting in a net margin of 8.8%.

AMPH - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Amphastar Pharmaceuticals, Inc. reported a net income of 6.42M and revenue of 171.17M, resulting in a net margin of 3.8%.


Frequently Asked Questions


XPEL and AMPH have a correlation of 0.29, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

AMPH has higher volatility (12.20%) compared to XPEL (11.25%). In terms of maximum drawdown, XPEL dropped -99.44% vs AMPH's -74.05%.

XPEL currently has the higher Sharpe Ratio (0.54 vs -0.45), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for XPEL and AMPH

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer